Skip to main content
TipRanks
Go Ultimate75% OFF

Pulse Biosciences (PLSE) AI Stock Analysis

292 Followers
PLSE

Pulse Biosciences

(NASDAQ:PLSE)

Select Model
Rating:60Neutral
Price Target:$49.00â–²(9.28% Upside)
Action:reiterated
Date:11/06/26

PLSE scores as a mid-range opportunity: strong, upbeat clinical/regulatory progress and a reinforced cash position support the outlook, and price action is trending positively. However, the overall score is held back by very weak current financial performance—large ongoing losses and substantial cash burn relative to a small revenue base—and valuation is constrained by negative earnings.

Positive Factors
Proprietary nsPFA platform and intellectual propertyA large owned patent estate and accumulated technical know-how can create durable barriers to entry in bioelectric medicine. The non-thermal platform’s focus on consistent lesions and reduced collateral injury may support differentiation, clinical adoption, and expansion across multiple procedures.
Negative Factors
Large losses and heavy cash burnThe current revenue base is not yet sufficient to support the company’s cost structure, leaving Pulse dependent on its cash balance and future capital access. Persistent losses and substantial cash burn could constrain investment choices, increase financing needs, and reduce financial flexibility before commercialization scales.

Pulse Biosciences (PLSE) vs. SPDR S&P 500 ETF (SPY)

-100%0%100%200%300%400%PLSE+254.19%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.30B
Dividend Yield
―
Average Volume (3M)
504.31K
Price to Earnings (P/E)
-37.1
Beta (1Y)
0.74
Revenue Growth
1637.21%
EPS Growth
-6.34%
Country
US
Employees
116
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Pulse Biosciences Business Overview & Revenue Model

Company Description

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary N...

Pulse Biosciences Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-15.51%|Next Earnings Date:May 11, 2022
Earnings Call SentimentPositive

The call was strongly optimistic, driven by completion of Nano-Pulse AF enrollment three months ahead of schedule, encouraging European efficacy data, substantial financing, expanding clinical programs, and active commercial-readiness investments. The company also reported higher operating losses, expected increases in quarterly spending, limited current commercial revenue, pending pivotal data and regulatory milestones, and remaining manufacturing scale-up work. Overall, the highlights significantly outweighed the lowlights.

Positive Updates

Nano-Pulse AF Enrollment Completed Ahead of Schedule
The U.S. pivotal Nano-Pulse AF IDE study completed enrollment in less than six months, three months ahead of the originally communicated timeline of nine months. The study enrolled 169 evaluable patients and 189 total patients, including 20 roll-ins, across 15 clinical sites and 36 investigators.

Negative Updates

Operating Losses Increased
GAAP net loss was $23.1 million in the third quarter of 2026 versus $19.4 million in the prior-year period. Non-GAAP net loss was $17.5 million versus $13.5 million in the prior-year period.

Company Guidance

Management expects final Nano-Pulse AF patient data based on blended 6-month and 12-month follow-up in Q3 2027, anticipates CE Mark approval occurring in Q4 of 2027, and is preparing to support a launch beginning in early 2028; it intends to submit the persistent AF IDE application in the fourth quarter of 2026 and remains on track to complete NANOCLAMP AF enrollment by the end of 1H 2027, with CE Mark approval for the clamp also anticipated in Q4 of 2027. The next-generation nPulse catheter is expected to undergo first-in-human evaluations in 2027, while the Vybrance parathyroid feasibility study will include 15 patients, the PTMC study is designed to enroll up to 30 patients, and additional PRECISE-BTN data are expected during 2027. At scale, gross margins on disposables are anticipated to exceed 70%, and quarterly non-GAAP costs and expenses are expected to increase by 15% to 25% above average Q2 and Q3 levels of approximately $20 million.

Pulse Biosciences Financial Statement Overview

Summary

Financials are dominated by large losses and heavy cash burn despite improving revenue. TTM revenue rose to about $1.5M (+26.1%), but net loss remains very large (about -$83.7M TTM) and operating cash flow/free cash flow are deeply negative (about -$63M TTM). The balance sheet is comparatively supportive with low debt (~$6.4M) versus sizable equity (~$183.6M), but ongoing losses imply continued reliance on external capital if the burn persists.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Mar 2022
Income Statement
Total Revenue1.49M350.00K00700.00K1.42M
Gross Profit141.00K-1.26M0-1.21M-11.24M-550.00K
EBITDA-83.26M-71.71M-52.41M-39.90M-57.15M-62.51M
Net Income-83.72M-72.78M-53.59M-42.21M-58.51M-63.66M
Balance Sheet
Total Assets201.58M94.54M132.46M59.15M77.88M54.25M
Cash, Cash Equivalents and Short-Term Investments189.19M80.73M118.04M44.37M61.14M28.61M
Total Debt6.36M7.53M8.90M9.14M75.96M11.25M
Total Liabilities18.01M13.88M17.60M14.79M80.13M18.56M
Stockholders Equity183.57M80.66M114.86M44.36M-2.25M35.69M
Cash Flow
Free Cash Flow-63.70M-54.44M-36.47M-33.16M-47.41M-54.53M
Operating Cash Flow-63.33M-54.12M-36.34M-33.04M-47.01M-54.10M
Investing Cash Flow-152.72M-335.00K-125.00K-121.00K-401.00K7.56M
Financing Cash Flow157.56M17.15M110.14M16.39M79.94M62.69M

Pulse Biosciences Technical Analysis

Technical Analysis SentimentNegative
Last Price44.84

Price Trends

50DMA51.64Negative
100DMA45.00Negative
200DMA33.66Positive

Market Momentum

MACD-0.39Positive
RSI38.38Neutral
STOCH5.35Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLSE, the sentiment is Negative. The current price of 44.84 is below the 20-day moving average (MA) of 52.85, below the 50-day MA of 51.64, and above the 200-day MA of 33.66, indicating a neutral trend. The MACD of -0.39 indicates Positive momentum. The RSI at 38.38 is Neutral, neither overbought nor oversold. The STOCH value of 5.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLSE.

Pulse Biosciences Risk Analysis

Pulse Biosciences disclosed 61 risk factors in its most recent earnings report. Pulse Biosciences reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.Q4, 2023
2.We may fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could cause our stock price to decline.Q4, 2023
3.If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed.Q4, 2023

Pulse Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PLSE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ATRCATRC73Outperform$2.80B183.582.93%―13.79%―
MMSIMMSI71Outperform$5.06B31.499.65%―9.34%33.77%
PLSEPLSE60Neutral$3.30B-37.05-77.88%―1637.21%-6.34%
TFXTFX57Neutral$6.33B19.249.74%0.85%-29.30%―
ANGOANGO52Neutral$483.21M-14.46-19.25%―8.20%-0.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
STXSSTXS46Neutral$88.96M-3.46-115.83%―4.83%15.55%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%PLSEANGOATRCMMSISTXSTFXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PLSE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PLSEPulse Biosciences Inc44.8431.83244.66%
ANGOAngiodynamics, Inc.11.49-0.41-3.45%
ATRCAtricure, Inc.55.0220.8460.97%
MMSIMerit Medical84.490.800.96%
STXSStereotaxis0.88-1.36-60.62%
TFXTeleflex159.5554.9252.49%

Pulse Biosciences Corporate Events

Product-Related Announcements

Pulse Biosciences Reports Positive Results from Thyroid Nodule Study

Positive
Nov 6, 2026

On November 6, 2026, Pulse Biosciences announced interim six-month results from the PRECISE-BTN study evaluating its nPulse Vybrance system for symptomatic benign thyroid nodules. Among 43 patients assessed, 86% achieved at least 50% nodule-volume re...

Business Operations and StrategyProduct-Related Announcements

Pulse Biosciences partners Clayman Thyroid Center on nsPFA

Positive
Oct 14, 2026

On October 14, 2026, Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, to deploy the nPulse Vybrance Percutaneous Electrode System in patient car...

Business Operations and StrategyProduct-Related Announcements

Pulse Biosciences Completes Enrollment in NANOPULSE-AF Trial

Positive
Oct 7, 2026

On October 7, 2026, Pulse Biosciences reported it had reached its enrollment goal of 164 evaluable patients in the NANOPULSE-AF IDE pivotal clinical study of its nPulse Cardiac Catheter System for drug-resistant, symptomatic, paroxysmal atrial fibril...

Business Operations and StrategyPrivate Placements and Financing

Pulse Biosciences Launches New ATM Equity Program

Neutral
Sep 15, 2026

On September 15, 2026, Pulse Biosciences entered into a new equity distribution agreement with Mizuho Securities USA, allowing the company to sell up to $85 million of common stock from time to time in at-the-market and other permitted transactions,...

Business Operations and StrategyProduct-Related Announcements

Pulse Biosciences Completes Enrollment in PRECISE-BTN Study

Positive
Sep 15, 2026

On September 15, 2026, Pulse Biosciences announced it had completed enrollment in its PRECISE-BTN clinical study of the nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules, expanding the trial from 50 to 100 patients...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026